PBPK Modelling for Intratumoral Biodistribution of Magnetic Iron Oxide Nanoparticles

Extended Abstract Iron oxide nanoparticles (NPs), particularly magnetic iron oxide (MIO) nanoparticles, may provide a potential therapeutic intervention in therapy, due to their ability to induce hyperthermia at sites in which they accumulate, such as solid mass tumours. Cancer cells respond significantly to the elevated temperature (hyperthermia) initiated by MIO, causing their shrinkage and death. However, it is essential to characterise MIO distribution and retention locally in the tumour mass after interstitial/intratumoral injection to more fully understand key aspects of their efficacy and safety profile. There is a paucity of studies that have fully elucidated dose-response profiles for MIO owing to the complexity of solid tumour physiology and MIO biodistribution characterisation locally, within the tumour. The work described here, has developed a novel mechanistic, and physiologically based pharmacokinetic (m-PBPK), improve quantitative pharmacokinetic predictions.